OOIR: Observatory of International Research

Papers

(The TQCC of JAMA Oncology is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
JAMA Oncology	825
Malignant Pericardial Effusion, or Fluid Around the Heart Due to Cancer	523
Analysis of Quality-of-Life Outcomes by Drug Class in Cancer Clinical Trials—Reply	411
Error in Text	330
Errors in Key Points and Abstract	326
Stargazers	322
Biomarker Analysis of Vistusertib Plus Paclitaxel Regimen	308
Sexual Rehabilitation Needs of Gay and Bisexual Men With Cancer	297
Overall Survival in the CAIRO5 Clinical Trial	275
Piercing the Fog	271
Concerns Regarding the Utility of High-Risk Pancreatic Cancer Surveillance—Reply	246
Methodology Concerns Regarding Claims Data Studies in Transgender Health—Reply	225
Limitations in Quantitative Harm-Benefit Assessment in Immuno-Oncology	221
The Implications of the Supreme Court Decision to Overturn Roe v Wade for Women With Pregnancy-Associated Cancers	215
Her Defiance	209
Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration	208
Firearm Safety for Patients Diagnosed With Cancer—A Role in Suicide Prevention	190
Established Cancer Predisposition Genes in Single and Multiple Cancer Diagnoses	169
Immunotherapy in Prepatients—Preventing or Promoting a Malignant Transformation?	167
Fovinaciclib for First-Line Therapy of Advanced Breast Cancer	167
Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab	163
The Multidisciplinary Cancer Conference	163
Nationwide Response to Carboplatin and Cisplatin Shortages in Lung Cancer	156
Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors	155
Less Can Be More by Circulating Tumor DNA Use in ERBB2 -Positive Breast Cancer	151

Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab	151
The Global Economic Cost of Cancer—Estimating It Is Just the First Step!	148
Radiation-Associated Secondary Cancer in Patients With Breast Cancer Harboring TP53 Germline Variants	144
Ribociclib Plus Endocrine Therapy in Hormone Receptor–Positive/ ERBB2 -Negative Early Breast Cancer	143
Transplant-Free Approach in Relapsed Hodgkin Lymphoma in Children, Adolescents, and Young Adults	142
Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia	135
Unrelated Donor Age and Recipient Outcomes After Posttransplant Cyclophosphamide vs Conventional Prophylaxis	132
Tumor-Infiltrating Clonal Hematopoiesis and Pan-Cancer Prognosis in Patients With Solid Tumors	129
Long-term Effect of Machine Learning–Triggered Behavioral Nudges on Serious Illness Conversations and End-of-Life Outcomes Among Patients With Cancer	125
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer	119
SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US	118
Association of 5α-Reductase Inhibitor Use With Prostate Cancer–Specific Mortality—Reply	115
The SOUND Randomized Clinical Trial Results	112
Results of the TARGET-TP Randomized Clinical Trial	110
Is Appendiceal Cancer a Lynch Syndrome–Associated Cancer?	107
Immunotherapy Before Chemoradiotherapy—More Is Better?	104
Shifting Toward Precision Oncology in SCLC Treatment	104
An Atypical Rash on the Chest	104
Unplanned Hospitalization Prediction During Chemoradiotherapy Via Machine Learning Classifiers—Reply	104
Trauma	103
JAMA Oncology	101
The Most Difficult Lesson From Cancer Just Might Be Its Most Valuable	101
Coding Errors in Study of Eligibility for Lung Cancer Screening	100
Unwinding of Medicaid Continuous Enrollment Exposes Millions to Disrupted Care—“Be Kind, Rewind”	98
Error in Text	97
Disparities in Trends of Gastroenteropancreatic Neuroendocrine Tumor Incidence	95
Steroid Dose and Duration, Immortal Time Bias, and Survival After High-grade Immune-Related Adverse Events—Reply	94
Caution Regarding Assessment of Toxic Effects and Survival in Treatment De-escalation With Radiotherapy vs Transoral Surgery for Human Papillomavirus–Associated Oropharyngeal Cancer	92
National Trends in Dexrazoxane and Cardiovascular Health Care Utilization for Children With Acute Myeloid Leukemia	91
JAMA Oncology	91
Magnetic Resonance Imaging or Confirmatory Biopsy for Patients With Prostate Cancer Receiving Active Surveillance	90
Variability in COVID-19 Vaccine Response Among People With Cancer	90
Clinical Trial Diversity—Will We Know It When We See It?	89
Undiagnosed Cancer Cases in the US During the First 10 Months of the COVID-19 Pandemic	89
Proton Craniospinal Irradiation for Patients With Leptomeningeal Metastasis	89
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent	89
Challenges in Interpreting MELATORCH Trial Outcomes—Reply	88
Second Primary Cancer After Chimeric Antigen Receptor–T-Cell Therapy	88
Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer	88
Reassessing Treatment Outcomes Following Immune-Related Adverse Events—Reply	87
RETRACTED: Rethinking End Points in Modern Oncology Trials—Beyond the P Value	87
Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia	86
Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers	84
Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer	83
Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma	83
Development and Validation of a Parsimonious Risk Stratification Model for Pancreatic Cancer	83
Natural Language Processing–Assessed Unmet Medical and Social Needs in Cancer Crowdfunding Stories	82
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma	80
Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms	80
BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients	80

Association Between Age and Survival Trends in Advanced Non–Small Cell Lung Cancer After Adoption of Immunotherapy	79
Project Optimus: Is the US Food and Drug Administration Waiving Dose Optimization for Orphan Drugs?	79
Prostate-Specific Membrane Antigen PET-Guided Intensification of Salvage Radiotherapy After Radical Prostatectomy	78
Trends in the Characteristics, Treatment, and Outcomes of Rectal Adenocarcinoma in the US From 2004 to 2019	78
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer	77
On Accelerated Aging—A Phenomenon in Survivors of Childhood Cancer	76
Change of Article Status to Open Access	75
Is the Delphi’s Oracle Pertinent to Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma?—Reply	73
JAMA Oncology	72
Challenges in Shared Care Research in Hematopoietic Cell Transplantation—Reply	71
Methodological Issues in Study of Daily Insulin Dose and Cancer Risk Among Patients With Type 1 Diabetes	71
Role of Patient-Reported Outcome Measures in the Inpatient Setting—Reply	71
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer—The A021501 Trial—Reply	71
“You’ve Got Mail”—Receiving Bad News Through a Patient Portal	69
Standardized Definitions for Efficacy End Points for Adjuvant Trials—The Updated STEEP Criteria	69
JAMA Oncology	69
Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma	68
Searching Beyond Programmed Cell Death Ligand 1 in Metastatic Breast Cancer—Still Haven’t Found What We’re Looking For	68
Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor–Positive Breast Cancer	68
Enlightening a Path Forward for Patients With Advanced Acral Melanoma	67
Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL	65
Consistent Adherence to Physical Activity Guidelines and Digestive System Cancer Risk and Mortality	65
Lullaby for a Dying Self	65
Caution Regarding Assessment of Toxic Effects and Survival in Treatment De-escalation With Radiotherapy vs Transoral Surgery for Human Papillomavirus–Associated Oropharyngeal Cancer	65
Three-Body Problem at Digital Frontiers	64
Young-Onset Colorectal Cancer Mortality by Education	61
Rates of and Factors Associated With Patient Withdrawal of Consent in Cancer Clinical Trials	61
Artificial Intelligence–Detected Tumor-Infiltrating Lymphocytes and Outcomes in Anti–PD-1–Based Treated Melanoma	61
The Children’s Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers	60
Endocrine Society Hypercalcemia of Malignancy Guidelines	60
Characterizing Lung Cancer in Li-Fraumeni Syndrome	59
Treatment of Adults With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia—From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens	59
Physical Activity, Lifestyle, and Cancer Risk	59
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer	58
Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non−Small Cell Lung Cancer	58
Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer	58
Sunsets	57
Overall Survival With Adjuvant mFOLFIRINOX for Pancreatic Cancer	57
JAMA Oncology	57
Global Stage Distribution of Breast Cancer at Diagnosis	57
Should DDGP Regimen Be the Standard of Care for Advanced Extranodal NK/T-Cell Lymphoma? The New Staging System Matters	57
JAMA Oncology	56
Valid Analysis of Brain-Specific Progression-Free Survival	56
Immunotherapy Benefit Over Best Supportive Care in Hepatocellular Cancer With Child-Pugh B Dysfunction—Reply	56
Errors in Figures 2 and 3	55
Relentless	55
Radiotherapy With a 12-Gene Expression Assay for Ductal Carcinoma In Situ	55
Antiandrogen Treatment vs Active Surveillance for Patients With Prostate Cancer—Reply	55
The Oncology Industrial Complex—Community Oncology Must Be Given a Seat at the Table—Reply	55
MGMT Promoter Methylation and Chemotherapy Outcomes in Low-Grade and Anaplastic Gliomas	55
Assessment of Phase 3 Randomized Clinical Trials Including Patients With Leptomeningeal Disease	54
The Vocabulary of Survival	53
Error in Denominator in Results Text	53
Shared Local Oncology Care After Allogeneic Hematopoietic Cell Transplantation	53
Cancer Research and Public Health Literacy—Making Sense	52
Managing Cancer Pain in Patients With Opioid Use Disorder or Nonmedical Opioid Use	52
Implementing Cancer Medicines on the WHO Model Lists of Essential Medicines Into National Systems	52
Prostate-Specific Membrane Antigen PET-Guided Salvage Radiotherapy—Precision or Prematurity?—Reply	51
Artificial Intelligence—From Starting Pilots to Scalable Privilege	50
Clonal Hematopoiesis and Risk of Trastuzumab-Related Cardiotoxic Effects	50
Oral Mucosal Pigmentation in a Patient With Mycosis Fungoides	50
Cost-Effectiveness of Adjuvant Immunotherapy in Cancer Treatments	50
Public Awareness of the Association Between Alcohol and Cancer in the US	50
The Time for Cancer Vaccines Is Now	50
Survival in the SONIA Trial—Reply	50
Management of Down Syndrome–Associated Leukemias	49
Reshuffle	49
Exploration of Clinician Perspectives on Multidisciplinary Tumor Board Function Beyond Clinical Decision-making	49
Smoking Status of the US Cancer Population and a New Perspective From the National Cancer Database	49
Comparing Risk for Second Primary Cancers After Intensity-Modulated vs 3-Dimensional Conformal Radiation Therapy for Prostate Cancer, 2002-2015	49
Recurrence of Non–Small Cell Lung Cancer With Visceral Pleural Invasion	48
Personalized Radiation Therapy—Spurning the “One Size Fits All” Approach	48
Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer	47
Effectiveness of Aerobic Exercise and Tai Chi Interventions on Sleep Quality in Patients With Advanced Lung Cancer	47
Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer	47
Immune Checkpoint Inhibitor Therapy Before Nephrectomy for Locally Advanced and Metastatic Renal Cell Carcinoma	47
Scattered Painful Papulonodules in an Older Woman	46
Genetic Testing in Men With Metastatic Castration-Resistant Prostate Cancer	46
Antiandrogen Treatment vs Active Surveillance for Patients With Prostate Cancer	46
JAMA Oncology	46

Integrating Community Health Workers Into Care for Patients With Advanced Stages of Cancer—Fragility Index Analysis	45
Advancing Truth in Oncology by Complementing Clinical Trials With Evidence From Clinical Practice	45
Change of Article Status to Open Access	44
The SOUND Randomized Clinical Trial Results—Reply	44
Errors in Figure 3	43
Locally Advanced Relapse May Not Be Equal to Stage 3 Non–Small Cell Lung Cancer	43
Error in Figure 1	43
Stereotactic Radiosurgery vs Conventional Radiotherapy for Spine Metastases	43
Two Hands, One Journey	43
Dog Aloisanov Helped Diagnose My Cancer	43
The Case for Allowing Proton Beam Therapy on Head and Neck Cooperative Group Studies	42
Somebody Else’s Palms	41
Immunotherapy Benefit Over Best Supportive Care in Hepatocellular Cancer With Child-Pugh B Dysfunction	41
Financial Toxicity Among Asian American Cancer Survivors	40
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer	40
Error in Figure 1	40
Error in Figure	40
Reassessing Treatment Outcomes Following Immune-Related Adverse Events—Reply	40
An Algorithm as a Biomarker for Response to Immune Checkpoint Inhibitor Therapy	40
Increasing the Uptake of Cancer Risk Management Strategies for Women With BRCA1/2 Sequence Variations	40
Unintended Consequences of Patient Portal Access	39
Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma	38
Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer	38
Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021	38
Cervical Cancer Incidence in the US-Affiliated Pacific Islands	38
Genetic Ancestry–Based Differences in Biomarker-Based Eligibility for Precision Oncology Therapies	38
PARP Inhibitors for Breast Cancer Treatment	38
Nine-Valent Human Papillomavirus Vaccination and Related Cancers in Males	38
Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases	37
Integrating Oncology Lessons Across Tumor Types From Kidney to Prostate—A Good-Risk Shift	37
Risk Factors for Valvulopathy Among Childhood Cancer Survivors	37
Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor–Positive/ERBB2-Positive Early Breast Cancer	37
Postoperative Restrictive Opioid Protocols and Durable Changes in Opioid Prescribing and Chronic Opioid Use	37
Association of Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy	37
Error in the Additional Contributions Section	36
Comment on Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer	36
Net Clinical Benefit as Measure of Treatment Benefit Among Older Adults With Advanced Incurable Non–Small Cell Lung Cancer—Reply	36
Assessing Response for Nivolumab Plus Ipilimumab in Squamous Cell Carcinoma of the Head and Neck—Reply	36
Change to Open Access Status	36
Racial Disparities and Survival Outcomes in Breast Cancer—Reply	36
Government Funding for the Development of Enzalutamide	36
A Case of Multiple Hemorrhagic Friable Nodules	36
Change to Open Access	36
Childhood Cancer Survivor Risk Estimates and Age, Overdispersion, and Social Context—Reply	36
Implementing Resource-Stratified Guidelines in LMICs—More Issues Than Solutions	35
Survival Without Adjuvant Therapy for Low-Risk Endometrial Cancer With Isolated Tumor Cells	35
Reexamining Social Determinants of Health Data Collection in the COVID-19 Era	35
JAMA Oncology	35
Overall Survival in the CAIRO5 Clinical Trial	35
A Paradigm Shift Toward Population-Based MRI-Targeted Prostate Cancer Screening	34
Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer	34
Blood Clots, or Thrombosis, in Patients With Cancer	34
Immunotherapy Strategies After Immune Checkpoint Inhibitor Exposure in Renal Cell Carcinoma	34
Age-Dependent Interplay of Modifiable Risk Factors and Genetic Risk in Pancreatic Cancer	33
High-Dose Aumolertinib for Untreated EGFR-Variant Non–Small Cell Lung Cancer With Brain Metastases	33
Atezolizumab and Trastuzumab Plus Chemotherapy for ERBB2-Positive Locally Advanced Resectable Gastric Cancer	33
Intraperitoneal and Intravenous Paclitaxel Plus S-1 for Gastric Cancer With Peritoneal Metastasis	33
Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases	33
Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care—Checking CHEK2	33
Association of Second-generation Antiandrogens With Cognitive and Functional Toxic Effects in Randomized Clinical Trials	33
Survival in the SONIA Trial	33
Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor–Positive, ERBB2-Negative Breast Cancer	32
Long-Term Toxicity of Immune Checkpoint Inhibitors—Time to Widen the Lens	32
Implementing Smoking Cessation Interventions for Tobacco Users Within Oncology Settings	32
Osimertinib in Patients With Non–Small Cell Lung Cancer and Uncommon EGFR Mutations—Chasing Unicorns?	32
Enhancing Clinical Cancer Research Through Sharing of Data and Biospecimens	32
Lazertinib in EGFR-Variant Non–Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors	31
Tepotinib Treatment in Patients With MET Exon 14–Skipping Non–Small Cell Lung Cancer	31
Charting the Path to Systemic Therapy De-escalation—Oligometastatic Kidney Cancer as a Paradigm	31
Results of the TARGET-TP Randomized Clinical Trial—Reply	30
Nontumor Cells in Tumor Samples Bias Expression-Based Models	30
Concerns Regarding the Utility of High-Risk Pancreatic Cancer Surveillance	30
Assessment and Prognostic Value of Inflammatory Biomarkers in Patients With Colon Cancer	30
JAMA Oncology—The Year in Review, 2023	30
Keeping the Heartbeat Off-Target in Cancer Therapy	30
Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?—Reply	30
Aiming for the Cure in ERBB2-Positive Metastatic Breast Cancer—Should We Go “All In”?	30
USPSTF Lung Cancer Screening Guidelines and Disparities in Screening Adherence	30
Postoperative Management of Prostate Cancer—Optimizing Prostate Cancer Care	30
Integrating Community Health Workers Into Care for Patients With Advanced Stages of Cancer—Fragility Index Analysis—Reply	30
Errors in Table	29
A Partnership to Advance Care of Patients With Acute Promyelocytic Leukemia	29
The Next Wave After Immunotherapy in Cancer Drug Development—Back to the Future	29
Omission of Critical Information From Clinical Trial Reports—What to Do About Uninterpretable Results	28
Muscle Mass, Fragility, Weight Loss, and Cancer Treatment	28
Caution Regarding Assessment of Toxic Effects and Survival in Treatment De-escalation With Radiotherapy vs Transoral Surgery for Human Papillomavirus–Associated Oropharyngeal Cancer	28
Improving Eligibility Criteria for Lung Cancer Screening—Promises, Challenges, and Unmet Needs	28
Sommelier	28
US Cancer Mortality Trends Among Hispanic Populations From 1999 to 2020	28
Watch and Wait for Near-Complete Responders—A Word of Caution	27
Gefitinib vs Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Variant Lung Cancer—Long-Term Results of a Randomized Clinical Trial	27
Cribriform-Positive and -Negative Prostate Cancer	27
Bilateral Oophorectomy and All-Cause Mortality in Women With BRCA1 and BRCA2 Sequence Variations	26
Misinterpretation of Surgeons’ Statements on Cancer Removal—The Adverse Effects of “We Got It All”	26
Temporal Trends in Lung Cancer Cases Diagnosed at Early Stage	26